APVO News and Press, Aptevo Therapeutics Inc. From 08/02/23

2023-08-02 08:58:27 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Aptevo Therapeutics (NASDAQ: APVO ) stock is sliding lower on Wednesday after the biotechnology company announced a public share offering . The APVO stock offering has t...

2023-08-02 05:35:42 ET Aptevo Therapeutics ( NASDAQ: APVO ) stock price dropped 25% as the company entered agreements with healthcare-focused institutional investors for the purchase and sale of ~8M shares at a purchase price of $0.62 per share. The company further agree...

SEATTLE, WA / ACCESSWIRE / August 1, 2023 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical stage biotechnology company focused on developing novel immuno-oncology therapeutics, today announced that the Company has entered into definitive agreements with healthcare...

2023-07-19 10:22:17 ET Gainers: Panbela Therapeutics ( PBLA ) +36% . 60 Degrees Pharmaceuticals ( SXTP ) +20% . CareMax ( CMAX ) +20% . Biodexa Pharmaceuticals ( BDRX ) +13% . bluebird bio ( BLUE ) +13% . Losers: Amar...

2023-07-18 10:13:56 ET Gainers: iCAD ( ICAD ) +31% . Biophytis ( BPTS ) +27% . Hyperfine ( HYPR ) +15% . Cabaletta Bio ( VERU ) +12% . Mind Medicine (MindMed) ( MNMD ) +10% . Losers: Lixte Biotechnology ( LIXT ) ...

Phase 2 Trials in Relapsed/Refractory and Frontline Settings Planned, APVO436 to be administered in Combination with Emerging Standard of Care New Data Adds to Growing Body of Clinical Evidence in Support of APVO436 Clinical Potential SEATTLE, WA / ACCESSWIRE / July 18, 2023 / Aptevo Th...

2023-05-11 09:24:36 ET Aptevo Therapeutics press release ( NASDAQ: APVO ): Q1 GAAP EPS of $0.26 beats by $1.45 . Aptevo had cash and cash equivalents as of March 31, 2023 totaling $25.3 million. For further details see: Aptevo Therapeutics GAAP EPS of $0.26 b...

Company Achieves Multiple Clinical and Preclinical Milestones and Raises $9.7 Million in Non-Dilutive Funding, Eliminates Balance Sheet Debt Introduces Novel Compound APVO711, Dual Mechanism of Action Includes Both Checkpoint Inhibitor and T Cell Stimulator SEATTLE, WA / ACCESSWIRE / May...

2023-03-30 09:10:45 ET Aptevo Therapeutics press release ( NASDAQ: APVO ): FY GAAP EPS of $1.57 beats by $0.64 . Revenue of $3.11M (-74.7% Y/Y) in-line. Aptevo had cash and cash equivalents as of December 31, 2022 totaling $22.6 million. For further details s...

2023-03-30 07:47:01 ET Aptevo Therapeutics ( NASDAQ: APVO ) has raised $9.6M in non-dilutive funding, extending its cash runway beyond 12 months with an additional $50K possible based on IXINITY sales in 1Q 23. The company raised this funding by closing a transaction ...